Intellia Therapeutics is trading 5.73% higher at $12.38 on October 8, 2026; no clear company-specific catalyst explaining the rise was found in available October 8 coverage.
- The broader market was lower, with the Nasdaq down 0.55% and the S&P 500 down 0.31%, not a same-direction explanation for the gain.
- Barclays initiated coverage on October 6 with an Underweight rating and an $8 target. This recent negative analyst news does not clearly explain the rise.